Editorial

Acupuncture and Herbal Medicine for Cancer Patients

S. Schröder,1 S. Lee,2 T. Efferth,3 and Y. Motoo4

1 HanseMerkur Center for Traditional Chinese Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
2 Department of Clinical Oncology, College of Korean Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea
3 Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany
4 Department of Medical Oncology, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan

Correspondence should be addressed to Y. Motoo; motoo@kanazawa-med.ac.jp

Received 27 October 2013; Accepted 27 October 2013

Copyright © 2013 S. Schröder et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Complementary and Alternative Medicine (CAM) in Cancer Care

In recent decades, cancer treatment has made remarkable progress with targeted therapy applied on targeted subpopulation [1]. Though the life expectancy of the general population is increasing, cancer is still one of the most common causes of death worldwide [2]. The sophisticated treatments are often accompanied with increased adverse events, and the survival rate is still unsatisfactory in some cancers. In advanced or recurrent cancers, the goal of cancer treatment is often not curing the disease but prolonging survival time with good quality of life. The health-related quality of life is getting value as a cancer outcome, and the effect of early palliative care is emphasized importantly [3]. Nowadays medical information is easily accessed by patients, and most of patients are looking for treatments with less side effects and all available information to prolong survival time and to improve quality of life. Therefore, complementary and alternative medicine (CAM) for cancer is increasingly being demanded by patients, and more physicians are getting interested in the use of CAM in cancer therapies.

The use of CAM in cancer therapies differs from country to country, but up to 80% of cancer patients use some kinds of CAM to support their conventional cancer treatments [4, 5]. In Southwestern China, the prevalence of Chinese herbal medicine use is up to 53.0% during cancer treatment [6], and it seems similar to that of Hong Kong [7]. In Taiwan, up to 98% of the cancer patients use any kind of CAM [8]. In Korea, 78.5% of cancer patients use CAM [9]. A Japanese study revealed that 44.6% of cancer patients use CAM [10], while 83% of cancer patients or cancer survivors use CAM treatments in Australia [11]. An European survey in 13 countries showed 35.9% of average CAM prevalence in cancer patients (range among countries 14.8% to 73.1%) [12]. In other parts of the world similar results were obtained [13]. CAM is also used by 31–84% of children with cancer [14]. This usage of CAM for cancer is more common among educated people with better health behaviour [15, 16] as well as among women [17]. In the case of female cancers, more patients use CAM; for example, 60–80% of breast cancer patients (in comparison to 50% among cancer patients in general) and 75% of female colon cancer patients use CAM [18].

Patients mostly use CAM as a complement to their conventional therapy, not as an alternative treatment [19]. Only very few patients replace conventional treatment by alternative medicine [20]. Even though the use of CAM is a fact worldwide, the view on CAM varies enormously, and the integration of CAM therapies into conventional therapies is extremely complicated in different countries.

Although the governmental support on the research on CAM for cancer therapies differs among various countries, the use of CAM for cancer patients is still debated in an ideological way by supporters and opponents of CAM. One of the causes for the reluctance of Western academia towards CAM is still the insufficient number of convincing clinical studies providing evidence for the efficacy and safety of CAM therapies. The Western concept of “evidence-based
Acupuncture and herbal treatment have been used as a complementary treatment in combination with highly effective and partly aggressive Western medicine such as chemotherapy or hormonal therapy. But interactions are quite unknown, underestimated, or under debate. For instance, the herbal treatment with hormone-active herbs in patients with hormone-sensitive cells of breast or ovarian cancers is an important topic of ongoing debates [46, 47]. The interaction of acupuncture and especially herbal medicine with conventional treatments is not all known. Guidance on the safety of herbal medicine to prevent potential risks to cancer patients is necessary, but data have not yet been collected systematically in Mainland China but are now being established in Hong Kong.

In Japan, Kampo, traditional Japanese medicine, is extensively used for cancer patients as supportive measures, covered by National Health Insurance. Japanese medical doctors...
can prescribe both Western and Kampo drugs, knowing the natural history of diseases and the indication and limitation of Kampo. But, there are no strong recommendations on the Kampo use based on high-quality evidence in clinical practice guidelines in Japan [48]. The Japanese medical system is a unitary one, and Kampo is practiced in this system. From this point of view, the system of Japanese traditional medicine is different from those of China and Korea, where traditional medicine is generally practiced in a dual system, but in the recent years integrative approaches were developed. Japanese Kampo practitioners take advantage of this unitary system, conducting high-quality clinical practice and research. This situation consequently leads to the integrative medicine by a single doctor, whereas the integrative medicine in other countries is usually done by a Western medicine doctor and a traditional medicine practitioner. The system of Japanese Kampo medicine well fits the methodologies of modern medicine, and many clinicians utilize Kampo, accumulating evidence data. This unified situation might be an inspiring example for countries with a unitary medical system.

In Korea, the government health insurance covers only acupuncture treatment for cancer patients. In Western countries, acupuncture and herbal medicine, in spite of frequent use, for years were not in the main focus of the medical academic society. So, research in this field was limited leading in consequence to a situation that especially treatments with Asian herbs often had a lack of scientific controls. But due to increasing interest of patients and practitioners, acupuncture had partly become an integrative therapy in pain management, and, for example, in Germany the use of Western herbs as a complementary medicine is common and Asian herbs are increasingly used.

Since herbal therapy is the most commonly used CAM treatment [49], in recent years, the search for active compounds has mainly focused on Asian herbs, whereby the emphasis has been on classical product-based leads for Western drug discovery, usually performed by screening the extracts or compounds from diverse biological sources. Many in vivo experiments showed effectiveness on cell cultures and in animal models [50–53], but translation from bench to bedside is still a difficult challenge. This research, mainly focusing on single active compound, has been done often without regard to preexisting knowledge of the therapeutic utility of the plant source [54]. While interactions of ingredients during the preparation procedure are sometimes essential to the therapy, an extraction of the active ingredients is often not a simple task, and evidence shows that single components extracted from plants are less potent than the crude extract [55]. Scientists of many countries worldwide have tried to apply modern experiment-based research methods to isolating active compounds from herbs, characterizing their pharmacodynamic and pharmacokinetic properties and defining their molecular modes of action with limited success. This reductionist paradigm of a "single chemical entity" is not easily applicable to the multidimensional complexity of Asian herbal prescriptions. Researchers often do not use any concepts of traditional theory as the basis for their investigations on these compounds [56].

Studies on the influence of single herbs or their components on different microbiological pathways of human physiology are necessary and important, but this research is not likely to lead to single-component treatments for multifactorial diseases such as cancer. Cancer is a systemic disease of the entire body. A single-target approach has limited effectiveness, and there is evidence that a multitarget approach might be more effective [57, 58]. It seems only rational to apply a multitargeted therapy to a multifactorial disease. The realization that multicomponent medicines may have advantages over single-component drugs has a scientific foundation. The pharmacological advantages of mixtures may lie in the potentiating action of their multiple bioactive components and the advancement of individualized therapy [59, 60].

Modern research methods on a single herb aimed at isolating active compounds from herb have to be the fundament for future researches in herbal medicine. But when basic information is found and made available, experiments with herbal combinations might be the productive direction for further research to control cancer. While cancer is a multifactorial disease with diverse heterogeneous mechanisms, a combination of components might provide a promising opportunity to focus on multiple targets. Furthermore, these efforts may eventually offer an individualized approach to the treatment. Basic research on single herbs and their active compounds is still essential for the scientific understanding of traditional herbal medicine. But research should not stop at this level but continue with research on multicomponents, their interactions, and increasing or decreasing activity in combinations. Gaining knowledge from tradition might be helpful, not ending in a dead end. This approach is ambitious and time-consuming but has a chance not to fail like conventional drug discovery procedure in the field of herbal medicine in recent years.

While it is difficult to get a patent on natural products, the further interest of pharmaceutical companies might be limited. Progress in this research area can only be found in intense national as well as international cooperation, founding international joint working groups to overcome the obstacles of this sophisticated challenge.

S. Schröder
S. Lee
T. Efferth
Y. Motoo

References

[1] R. Siegel, C. DeSantis, K. Virgo, K. Stein, A. Mariotto, and T. Smith, “Cancer treatment and survivorship statistics, 2012,” CA Cancer Journal for Clinicians, vol. 62, pp. 220–241, 2012.
[2] M. Malvezzi, P. Bertuccio, F. Levi, C. La Vecchia, and E. Negri, “European cancer mortality predictions for the year 2013,” Annals of Oncology, vol. 24, no. 3, pp. 792–800, 2013.
[3] J. S. Temel, J. A. Greer, A. Muzikansky et al., “Early palliative care for patients with metastatic non-small-cell lung cancer,” The New England Journal of Medicine, vol. 363, no. 8, pp. 733–742, 2010.
Evidence-Based Complementary and Alternative Medicine

[4] E. Ernst and B. R. Cassileth, “The prevalence of complementary/alternative medicine in cancer: a systematic review,” *Cancer*, vol. 83, no. 4, pp. 777–782, 1998.

[5] H. Boon, J. B. Brown, A. Gavin, M. A. Kennard, and M. Stewart, “Breast cancer survivors’ perceptions of complementary/alternative medicine (CAM): making the decision to use or not to use,” *Qualitative Health Research*, vol. 9, no. 5, pp. 639–653, 1999.

[6] T. G. Liu, S. Q. Xiong, Y. Yan, H. Zhu, and C. Yi, “Use of Chinese herb medicine in cancer patients: a survey in Southwestern China,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2012, Article ID 769042, 7 pages, 2012.

[7] Y.-C. Lam, C.-W. Cheng, H. Peng, C.-K. Law, X. Huang, and Z. Bian, “Cancer patients’ attitudes towards Chinese medicine: a Hong Kong survey,” *Chinese Medicine*, vol. 4, article 25, 2009.

[8] C. Yang, L.-Y. Chien, and C.-J. Tai, “Use of complementary and alternative medicine among patients with cancer receiving outpatient chemotherapy in Taiwan,” *Journal of Alternative and Complementary Medicine*, vol. 14, no. 4, pp. 413–416, 2008.

[9] M. J. Kim, S. D. Lee, D. R. Kim et al., “Use of complementary and alternative medicine among Korean cancer patients,” *Korean Journal of Internal Medicine*, vol. 19, no. 4, pp. 250–255, 2004.

[10] I. Hyodo, N. Amano, K. Eguchi et al., “Nationwide survey on complementary and alternative medicine use among adults and children: United States,” *JAMA Oncology*, vol. 9, no. 5, pp. 639–643, 2017.

[11] C. M. Gray, A. W. H. Tan, N. P. Pronk, and P. J. O’Connor, “Complementary and alternative medicine use among health plan members. A cross-sectional survey,” *Effective Clinical Practice*, vol. 5, no. 1, pp. 17–22, 2002.

[12] R. L. Nahin, J. M. Dahlhamer, B. L. Taylor et al., “Health behaviors and risk factors in those who use complementary and alternative medicine,” *BMC Public Health*, vol. 7, article 217, 2007.

[13] D. M. Upchurch, L. Chyu, G. A. Greendale et al., “Complementary and alternative medicine use among American women: findings from the National Health Interview Survey, 2002,” *Journal of Women’s Health*, vol. 16, no. 1, pp. 102–113, 2007.

[14] C. Lawsin, K. DuHamel, S. H. Itzkowitz et al., “Demographic, medical, and psychosocial correlates to CAM use among survivors of colorectal cancer,” *Supportive Care in Cancer*, vol. 15, no. 5, pp. 557–564, 2007.

[15] V. B. Konkimalla and T. Efferth, “Evidence-based Chinese medicine for cancer therapy,” *Journal of Ethnopharmacology*, vol. 116, no. 2, pp. 207–210, 2008.

[16] T. Efferth and B. Kaina, “Toxicities by herbal medicines with emphasis to traditional Chinese medicine,” *Current Drug Metabolism*, vol. 12, no. 10, pp. 989–996, 2011.

[17] A. Molassiotis, M. Brownall, L. Milovics, V. Panteli, E. Patiraki, and P. Fernandez-Ortega, “Complementary and alternative medicine use in patients with gynaecological cancers in Europe,” *International Journal of Gynecological Cancer*, vol. 16, supplement 1, pp. 219–224, 2006.

[18] G. A. Saxe, L. Madlensky, S. Kealey, D. P. H. Wu, K. L. Freeman, and J. P. Pierce, “Disclosure to physicians of CAM use by breast cancer patients: findings from the women’s healthier eating and living study,” *Integrative Cancer Therapies*, vol. 7, no. 3, pp. 122–129, 2008.

[19] G. Deng, B. R. Cassileth, and K. S. Yeung, “Complementary therapies for cancer-related symptoms,” *Journal of Supportive Oncology*, vol. 2, no. 5, pp. 419–426, 2004.

[20] J. M. Ezzo, M. A. Richardson, A. Vickers et al., “Acupuncture for xerostomia: clinical update,” *Cochrane Database of Systematic Reviews*, vol. 21, no. 22, pp. 4120–4126, 2003.

[21] G. Yang, X. Li, X. L. Li et al., “Traditional Chinese medicine in cancer care: a review of case series published in the Chinese literature,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2012, Article ID 751046, 8 pages, 2012.

[22] J. M. Ezzo, M. A. Richardson, A. Vickers et al., “Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting,” *Cochrane Database of Systematic Reviews*, vol. 22, no. 2, pp. 138–141, 2006.

[23] S. L. Dibble, J. Luce, B. A. Cooper et al., “Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies,” *Oncology Nursing Forum*, vol. 34, no. 4, pp. 813–820, 2007.

[24] T. S. K. Mok, W. Yeo, P. J. Johnson et al., “A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity,” *Annals of Oncology*, vol. 18, no. 4, pp. 768–774, 2007.

[25] P. A. S. Johnstone, Y. P. Peng, B. C. May, W. S. Inouye, and R. C. Niemtzow, “Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies,” *International Journal of Radiation Oncology Biology Physics*, vol. 50, no. 2, pp. 353–357, 2001.

[26] P. A. S. Johnstone, R. C. Niemtzow, and R. H. Riffenburgh, “Acupuncture for xerostomia: clinical update,” *Cancer*, vol. 94, no. 4, pp. 1151–1156, 2002.

[27] S. Schroeder, G. Meyer-Hamme, and S. Eplière, “Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN)—a pilot study using neurography,” *Acupuncture in Medicine*, vol. 30, no. 1, pp. 4–7, 2012.

[28] W. T. Y. Luo, L. Jin, L. W. C. Chow, M. N. B. Cheung, and M. Wang, “Rhodiola alpida improves chemotherapy-induced oral mucositis in breast cancer patients,” *Expert Opinion on Investigational Drugs*, vol. 19, supplement 1, 2009, pp. S91–S100, 2010.
Evidence-Based Complementary and Alternative Medicine

[35] A. J. Vickers, D. J. Straus, B. Fearon, and B. R. Cassileth, "Acupuncture for postchemotherapy fatigue: a phase II study," *Journal of Clinical Oncology*, vol. 22, no. 9, pp. 1731–1735, 2004.

[36] C. P. Escalante, T. Grover, B. A. Johnson et al., "A fatigue clinic in a comprehensive cancer center design and experiences," *Cancer*, vol. 92, supplement 6, pp. 1708–1713, 2001.

[37] J. Filshie, K. Penn, S. Ashley, and C. L. Davis, "Acupuncture for the relief of cancer-related breathlessness," *Palliative Medicine*, vol. 10, no. 2, pp. 145–150, 1996.

[38] J.-H. Kang, K.-H. Song, J.-K. Woo et al., "Ginsenoside Rp1 from Panax ginseng in ameliorating chemotherapy-induced nausea—randomized controlled study," *Annals of Oncology*, vol. 23, no. 5, pp. 1353–1361, 2012.

[39] J. P. Liu, M. Zhang, W. Y. Wang, and S. Grimsgaard, "Chinese herbal medicines for type 2 diabetes mellitus," *Cochrane Database of Systematic Reviews*, no. 3, Article ID CDR003642, 2004.

[40] A. Enblom, A. Johnsson, M. Hammar, E. Onel¨ov, G. Steineck, and S. Börjeson, "Acupuncture compared with placebo acupuncture in radiotherapy-induced nausea—a randomized controlled study," *Annals of Oncology*, vol. 23, no. 5, pp. 1353–1361, 2012.

[41] W. C. S. Cho, "Scientific evidence on the supportive cancer care with chinese medicine," *Chinese Journal of Lung Cancer*, vol. 13, no. 3, pp. 190–194, 2010.

[42] S. G. Li, H. Y. Chen, C. S. Ou-Yang et al., "The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced nonsmall cell lung cancer: a systematic review and meta-analysis," *PLoS One*, vol. 8, no. 2, Article ID e57604, 2013.

[43] B. R. Cassileth, G. E. Deng, J. E. Gomez, P. A. S. Johnstone, N. Kumar, and A. J. Vickers, "Complementary therapies and integrative oncology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)," *Chest*, vol. 132, no. 3, pp. 340–354, 2007.

[44] Y. J. Lee, Y. R. Jin, W. C. Lim et al., "Ginsenoside-Rh1 acts as a weak phytoestrogen in MCF-7 human breast cancer cells," *Archives of pharmacal research*, vol. 26, no. 1, pp. 58–63, 2003.

[45] J.-H. Kang, K.-H. Song, J.-K. Woo et al., "Ginsenoside Rf1 from panax ginseng exhibits anti-cancer activity by down-regulation of the IGF-1R/Akt pathway in Breast Cancer Cells," *Plant Foods for Human Nutrition*, vol. 66, no. 3, pp. 298–305, 2011.

[46] Y. Motoo, I. Arai, I. Hyodo, and K. Tsutani, "Current status of Kampo (Japanese herbal) medicines in Japanese clinical practice guidelines," *Complementary Therapies in Medicine*, vol. 17, no. 3, pp. 147–154, 2009.

[47] H. A. Tindle, R. B. Davis, R. S. Phillips, and D. M. Eisenberg, "Trends in use of complementary and alternative medicine by us adults: 1997–2002," *Alternative Therapies in Health and Medicine*, vol. 11, no. 1, pp. 42–49, 2005.

[48] Y. Maimon, V. Karash, N. Yaal-Hahoschen et al., "Effect of Chinese herbal therapy on breast cancer adenocarcinoma cell lines," *Journal of International Medical Research*, vol. 38, no. 6, pp. 2033–2039, 2010.

[49] S. Guan, W. Su, N. Wang, P. Li, and Y. Wang, "A potent tyrosinase activator from radix polygoni multiflori and its melanogenesis stimulatory effect in B16 melanoma cells," *Phytotherapy Research*, vol. 22, no. 5, pp. 660–663, 2008.

[50] C.-C. Lin, C.-L. Kuo, M.-H. Lee et al., "Extract of Hedyotis diffusa Wild influences murine leukemia WEHI-3 cells in vivo as well as promoting T- and B-cell proliferation in leukemic mice," *In Vivo*, vol. 25, no. 4, pp. 633–640, 2011.

[51] R. Min, J. Tong, Y. Wenjun et al., "Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca-8113 cell lines by Shikonin was partly through the inactivation of NF-kB pathway," *Phytotherapy Research*, vol. 22, no. 3, pp. 407–415, 2008.

[52] D. M. Eisenberg, E. S. J. Harris, B. A. Littlefield et al., "Developing a library of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biological evaluation—rationale, methods and preliminary results from a Sino-American collaboration," *Fitoterapia*, vol. 82, no. 1, pp. 17–33, 2011.

[53] Q. Luo, Y. Cai, J. Yan, M. Sun, and H. Corke, "Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts from Lycium barbarum," *Life Sciences*, vol. 76, no. 2, pp. 137–149, 2004.

[54] S. Guan, W. Su, N. Wang, P. Li, and Y. Wang, "A potent tyrosinase activator from radix polygoni multiflori and its melanogenesis stimulatory effect in B16 melanoma cells," *Phytotherapy Research*, vol. 22, no. 5, pp. 660–663, 2008.

[55] C.-C. Lin, C.-L. Kuo, M.-H. Lee et al., "Extract of Hedyotis diffusa Wild influences murine leukemia WEHI-3 cells in vivo as well as promoting T- and B-cell proliferation in leukemic mice," *In Vivo*, vol. 25, no. 4, pp. 633–640, 2011.

[56] R. Min, J. Tong, Y. Wenjun et al., "Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca-8113 cell lines by Shikonin was partly through the inactivation of NF-kB pathway," *Phytotherapy Research*, vol. 22, no. 3, pp. 407–415, 2008.

[57] D. M. Eisenberg, E. S. J. Harris, B. A. Littlefield et al., "Developing a library of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biological evaluation—rationale, methods and preliminary results from a Sino-American collaboration," *Fitoterapia*, vol. 82, no. 1, pp. 17–33, 2011.

[58] Q. Luo, Y. Cai, J. Yan, M. Sun, and H. Corke, "Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts from Lycium barbarum," *Life Sciences*, vol. 76, no. 2, pp. 137–149, 2004.

[59] S. Guan, W. Su, N. Wang, P. Li, and Y. Wang, "A potent tyrosinase activator from radix polygoni multiflori and its melanogenesis stimulatory effect in B16 melanoma cells," *Phytotherapy Research*, vol. 22, no. 5, pp. 660–663, 2008.

[60] C.-C. Lin, C.-L. Kuo, M.-H. Lee et al., "Extract of Hedyotis diffusa Wild influences murine leukemia WEHI-3 cells in vivo as well as promoting T- and B-cell proliferation in leukemic mice," *In Vivo*, vol. 25, no. 4, pp. 633–640, 2011.

[61] R. Min, J. Tong, Y. Wenjun et al., "Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca-8113 cell lines by Shikonin was partly through the inactivation of NF-kB pathway," *Phytotherapy Research*, vol. 22, no. 3, pp. 407–415, 2008.

[62] D. M. Eisenberg, E. S. J. Harris, B. A. Littlefield et al., "Developing a library of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biological evaluation—rationale, methods and preliminary results from a Sino-American collaboration," *Fitoterapia*, vol. 82, no. 1, pp. 17–33, 2011.

[63] Q. Luo, Y. Cai, J. Yan, M. Sun, and H. Corke, "Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts from Lycium barbarum," *Life Sciences*, vol. 76, no. 2, pp. 137–149, 2004.